Senores Pharmaceuticals Limited — Updates, 12-08-2025: Press Release

Senores Pharma (SPL), through its US subsidiary, has acquired two USFDA-approved drug applications (ANDAs) from Teva Pharmaceuticals USA. This strategic acquisition enhances SPL's product portfolio with a significant addressable market opportunity in the USA, estimated at ~USD 38 million (IQVIA, Dec 2024 MAT) and ~USD 120 million (Symphony, June 2025 MAT). The acquisition is funded by SPL's IPO proceeds, aligning with its stated objectives, and strengthens its presence in the US market.